STK17A knockdown results in decreased cisplatin-mediated apoptotic cell death. A, cell cycle analysis of NT2/D1 control, NT2-PLK, and NT2-STK17A-sh2 cells indicates fewer apoptotic sub-G1 cells upon cisplatin (Cispl) treatment of STK17A knockdown cells compared with control cells, whereas cell cycle phase distributions are similar. B, graph of data in A along with additional cisplatin dosages. Tx, treatment; Cont, control.